Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | MLYCD | O95822 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14696502 | 0.76 | EPHX2 (0.48) | HTTEPHX2MEN1KMT2AGLA | |
| SCHEMBL16064965 | 0.76 | HTT (0.60) | KDM4EHTTEPHX2POLBMEN1 | |
| SCHEMBL12137848 | 0.76 | EPHX2 (0.44) | KDM4EHTTEPHX2MEN1KMT2A | |
| SCHEMBL8879807 | 0.76 | KDM4E (1.00) | KDM4EHTTEPHX2POLBMEN1 | |
| SCHEMBL27617726 | 0.75 | EPHX2 (0.51) | EPHX2MEN1KMT2AMLYCD | |
| Hydrochloric Acid SCHEMBL1677927 | 0.74 | EPHX2 (0.50) | EPHX2MEN1KMT2AMLYCD | |
| SCHEMBL17755397 | 0.74 | HTT (0.57) | KDM4EHTTEPHX2POLBMEN1 | |
| SCHEMBL6891227 | 0.73 | ALDH1A1 (0.62) | KDM4EHTTEPHX2POLBMEN1 | |
| SCHEMBL16064957 | 0.73 | HTT (0.54) | KDM4EHTTPOLBMEN1KMT2A | |
| SCHEMBL28334704 | 0.72 | KDM4E (0.68) | KDM4EHTTEPHX2POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200159115-A1 | NOVEL SALT COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION, AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200159115-A1 | NOVEL SALT COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION, AND PATTERNING PROCESS | ETV6, EEF2, EEF1G | KDM4E 522/4885HTT 2117/4885EPHX2 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.